NCT06166134

Brief Summary

Radiological evaluation of sarcopenia in patients receiving chemotherapy

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
72

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 2, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 12, 2023

Completed
20 days until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

December 12, 2023

Status Verified

December 1, 2023

Enrollment Period

1.2 years

First QC Date

December 2, 2023

Last Update Submit

December 8, 2023

Conditions

Sarcopenia

Outcome Measures

Primary Outcomes (1)

  • Radiological evaluation of sarcopenia in patients receiving chemotherapy

    Using sonoelastography and computed tomography in evaluation of muscle mass in patients received chemotherapy by measurement of muscle thickness ,echogencity ,cross sectional area ,fasicle length,pennation angle, strain ratio,shear wave velocity

    April 2025

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Comparison of muscle mass before and after chemotherapy by use of sonoelastography and computed tomography and comparison with normal volunteer

You may qualify if:

  • all cancer patients receiving chemotherapy referred to radiodiagnosis department for routine examination Patients must be between 18 and

You may not qualify if:

  • Previous or current history of any musculoskeletal or neurological disorder including strokes.
  • Systemic atrophy affecting CNS ( Huntington disease ,hereditary ataxia ,spinal muscular disorder and related syndromes ,post polio syndrome )
  • Central nervous system demyelinating disease ( Multiple sclerosis , acute disseminated demyelinated syndromes..
  • Corticosteroids undertaken currently or for the past 3 years with doses \>5mg/day.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Links

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Lamiaa Refaat, Assisstant professor

    Assiut university -south egypt cancer institute

    STUDY DIRECTOR

  • Omar Mostafa, Assisstant professor

    Assiut university -south egypt cancer institute

    STUDY DIRECTOR

Central Study Contacts

Doaa Maher ebied Maher, Resident

CONTACT

01050147500dm953407@gmail.com

Hasan ibrahim Megally, Professor

CONTACT

01006209584Hasanibrahim48@yahoo.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

December 2, 2023

First Posted

December 12, 2023

Study Start

January 1, 2024

Primary Completion

April 1, 2025

Study Completion

April 1, 2025

Last Updated

December 12, 2023

Record last verified: 2023-12